期刊文献+
共找到696篇文章
< 1 2 35 >
每页显示 20 50 100
Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug 被引量:3
1
作者 Mari Hagiwara Keiko Kataoka +3 位作者 Hideki Arimochi Tomomi Kuwahara Haruyuki Nakayama Yoshinari Ohnishi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第7期1040-1043,共4页
AIM: Nonsteroidal anti-inflammatory drugs (NSAIDs)cause gastrointestinal damage as one of their side effects in humans and experimental animals. Lipid peroxidation plays an important role in NSAID-induced ulceration. ... AIM: Nonsteroidal anti-inflammatory drugs (NSAIDs)cause gastrointestinal damage as one of their side effects in humans and experimental animals. Lipid peroxidation plays an important role in NSAID-induced ulceration. The aim of this study was to investigate the inhibitory effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)reductase inhibitors on the ulceration in small intestines of rats.METHODS: The effects of three HMG-CoA reductase inhibitors, fluvastatin, pravastatin and atorvastatin on ileal ulcer formation in 5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl) thiophene (BFMeT)-treated rats were examined. Antioxidative activity of the inhibitors was measured by a redox-linked colorimetric method.RESULTS: Fluvastatin, which was reported to have antioxidative activity, repressed the ileal ulcer formation in rats treated with BFMeT an NSAIDs. However, the other HMG-CoA reductase inhibitors (pravastatin and atorvastatin)did not repress the ileal ulcer formation. Among these HMG-CoA reductase inhibitors, fluvastatin showed a significantly stronger reducing power than the others(pravastatin, atorvastatin).CONCLUSION: Fluvastatin having the antioxidaitive activity suppresses ulcer formation in rats induced by NSAIDs. 展开更多
关键词 Ileal ulcer fluvastatin HMG-CoA reductase inhibitors Nonsteroidal antiinflammatory drug
暂未订购
A near-infrared fluorescent probe for monitoring fluvastatin-stimulated endogenous H_2S production 被引量:4
2
作者 Li-Li Zhang Hui-Kun Zhu +1 位作者 Chun-Chang Zhao Xian-Feng Gu 《Chinese Chemical Letters》 SCIE CAS CSCD 2017年第2期218-221,共4页
Most reported fluorescent probes have limitations in practical applications in living systems due to the strong autofluorescence background,construction of probes with near-infrared(NIR) fluorescence emission is an ... Most reported fluorescent probes have limitations in practical applications in living systems due to the strong autofluorescence background,construction of probes with near-infrared(NIR) fluorescence emission is an accessible approach for addressing this challenge.We here designed a NIR fluorescent probe for monitoring the endogenous production of H2S in living cells.The designed probe showed significant NIR fluorescence turn-on response to H2S with high selectivity,enabling the sensitive detection H2S.Importantly,the probe could be applied in monitoring the endogenous production of H2S in raw 264.7 macrophages.This study showed that fluvastatin can promote the activity of cystathionineγ-lyase(CSE) for generation H2S. 展开更多
关键词 Fluorescent probe Near-infrared fluorescence emission Endogenous H2S detection fluvastatin
原文传递
Expression of Serum and Glucocorticoid-inducible Kinase1 in Diabetic Rats and Its Modulation by Fluvastatin 被引量:1
3
作者 王学彬 罗长青 +3 位作者 刘建社 张春 王玉梅 朱忠华 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2005年第6期651-654,共4页
The expression of serum and glucocorticoid-induced protein kinase in the renal cortex of diabetic rats was examined, and the function of signal transduction mediated by SGK1 in diabetic nephropathy and its modulation ... The expression of serum and glucocorticoid-induced protein kinase in the renal cortex of diabetic rats was examined, and the function of signal transduction mediated by SGK1 in diabetic nephropathy and its modulation by fluvastatin were also investigated. 24 male Wistar rats were randomly divided into normal control group (n = 8), diabetic nephropathy group (n = 8) and fluvastatin-treated diabetic nephropathy group (15 mg/kg/d, n=8). The metabolic parameters were measured at the 8th week. The expression of transforming growth factor β1 (TGF-β1) and fibronectin (FN) was immunohistochemically examined. The expression of SGK1 was detected by RT-PCR and Western blot, and CTGF mRNA was assessed by RT-PCR. As compared to DN, blood glucose, 24-h urinary protein, Cer and kidney weight index were all decreased and the weight was increased obviously in group F. At the same time, mesangial cells and extracellular matrix proliferation were relieved significantly. The levels of cortex SGK1 mRNA and protein were up-regulated, and both TGF-β1 and FN were down-regulated by fluvastatin. The mRNA of SGK1 was positively correlated with the CTGF, TGF-β1 and FN. SGK1 expression is markedly up-regulated in the renal cortex of DN group and plays an important role in the development and progress of diabetic nephropathy by means of signal transduction. Fluvastatin suppressed the increased SGKlmRNA expression in renal cortex and postponed the development of diabetic nephropathy. 展开更多
关键词 serum and glucocorticoid-inducible kinase connective tissue growth factor diabetic nephropathy fluvastatin
暂未订购
The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations 被引量:1
4
作者 Qian Xiang Weidang Wu +10 位作者 Nan Zhao Chuan Li Junyu Xu Lingyue Ma Xiaodan Zhang Qiufen Xie Zhuo Zhang Jiancheng Wang Weiren Xu Xia Zhao Yimin Cui 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2020年第2期264-272,共9页
The purpose of the present study was to investigate the impact of genetic polymorphism on fluvastatin pharmacokinetics.In addition,we compared the fluvastatin pharmacokinetics differences between extended-release(ER)8... The purpose of the present study was to investigate the impact of genetic polymorphism on fluvastatin pharmacokinetics.In addition,we compared the fluvastatin pharmacokinetics differences between extended-release(ER)80 mg tablet and immediate-release(IR)40 mg capsule in terms of drug metabolism enzyme and transporter genetic polymorphisms.In this open-label,randomized,two-period,two-treatment,crossover study(n=24),effects of ABCG2,SLCO1B1,ABCB1,CYP2C9 and CYP3A5 polymorphisms on the pharmacokinetics of fluvastatin were analyzed.The administration dosage for IR 40 mg and ER 80 mg were twice and once daily,respectively,for total 7 d.Blood samples for pharmacokinetic evaluation were taken on the 1st and 7th d.The lower exposure following ER was observed.For ER tablets,SLCO1B1 T521C genotype correlated with AUC 0-24 of repeat doses(P=0.010).SLCO1B1 T521C genotype had no statistically significant effect on AUC 0-24 of IR capsule of fluvastatin after single or repeated doses.In vitro study demonstrated that when the concentration of fluvastatin was low(<1μmol/l),the uptake of fluvastatin in the HEK293-OATP1B1 with SLCO1B1521TT(K m=0.18μmol/l)was faster than that with SLCO1B1521CC(K m=0.49μmol/l),On the other hand,when concentration reached to higher level(>1μmol/l),transport velocity of fluvastatin by HEK293-OATP1B1 with SLCO1B1521TT(K m=11.4μmol/l)and with SLCO1B1521TCC(K m=15.1μmol/l)tend to be the same.It suggests that the increased effect of SLCO1B1 T521C genotype on ER formulation of fluvastatin was mainly caused by lower blood concentrations.We recommend that formulation should be incorporated into future pharmacogenomics studies. 展开更多
关键词 Genetic polymorphisms SLCO1B1 fluvastatin Immediate-release EXTENDED-RELEASE
暂未订购
Inhibitory Effects of NO-Fluvastatin on Proliferation of Human Lens Epithelial Cells in vitro by Modulating Cell Cycle Regulatory Proteins 被引量:1
5
作者 王智 高瑞莹 +3 位作者 时倩倩 黄渝侃 陈雯 时开英 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2008年第5期588-591,共4页
The effects of NO-Fluvastatin on proliferation of human lens epithelial cells (HLECs) and the action mechanism were investigated. Cell proliferation was assessed by MTT assay. Cell cycle was analyzed by flow cytomet... The effects of NO-Fluvastatin on proliferation of human lens epithelial cells (HLECs) and the action mechanism were investigated. Cell proliferation was assessed by MTT assay. Cell cycle was analyzed by flow cytometry. The expression of cell cycle regulatory proteins CyclinE mRNA and P21waf1 mRNA was detected by reverse transcription polymerase chain reaction (RT-PCR). MTT staining colorimetry showed that HLECs proliferation was markedly inhibited by NO-Fluvastatin and the effect was dependently related to time (24, 48 and 72 h) and dosage (1, 5 and 20 μmol/L). Flow cytometry revealed that NO-Fluvastatin could significantly block HLECs in the G0/G1 phase, resulting in the increased cells in the G0/G1 phase and decreased in the S phase (P〈0.05). RT-PCR showed that NO-Fluvastatin could obviously inhibit the CyclinE mRNA expression and induce the P21waf1 mRNA expression as compared with the negative control groups (P〈0.05). This experiment suggested that NO-Fluvastatin could suppress the proliferation of HLECs by regulating cell cycle regulatory proteins (inhibiting the expression of CyclinE mRNA and inducing the expression of P21waf1 mRNA), resulting in the arrest of HLECs in the G0/G1 phase, which can offer theory basis for NO-Fluvastatin in treating posterior capsular opacification in clinic practice. 展开更多
关键词 posterior capsular opacification NO-fluvastatin human lens epithelial cell cell cycle regulatory protein
暂未订购
Fluvastatin protects against puromycin aminonucleoside-induced podocyte injury by inhibiting TRPC6
6
作者 Hui Gao Yunjing Zhang +1 位作者 Jing Lin Xifeng Sun 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2022年第5期360-368,共9页
In the present study,we aimed to investigate the effect of puromycin aminonucleoside(PAN)on the expression and distribution of transient receptor potential canonical 6(TRPC6)of murine podocytes and further study the p... In the present study,we aimed to investigate the effect of puromycin aminonucleoside(PAN)on the expression and distribution of transient receptor potential canonical 6(TRPC6)of murine podocytes and further study the protective mechanism of fluvastatin on podocyte injury by TRPC6 in vitro.Podocytes were treated by PAN at different doses and at different time points.The expressions of TRPC6 at mRNA and protein levels were assessed.An immunofluorescent assay was used to observe the distribution of TRPC6.Cultured podocytes were then divided into four groups.The expressions of TRPC6 at mRNA and protein levels were measured.The intracellular calcium concentration of podocytes was measured with a laser-scanning confocal microscope.The paracellular permeability to BSA was evaluated using Millicell-PCF Inserts.The expressions of TRPC6 at mRNA and protein levels were increased in a dose and time-dependent manner after exposure to PAN.Immunofluorescence showed that the expression intensity of TRPC6 was significantly increased,and the distribution of TRPC6 was changed after PAN was applied to podocytes.With fluvastatin intervention,PAN-induced up-regulation of TRPC6 was significantly reversed.The ratio of the peak value of intracellular calcium to the basic calcium value in the PAN group was significantly higher after TRPC6 was activated by OAG,while it is obviously reversed under the action of fluvastatin.The podocyte permeability was significantly increased after 48 h of PAN treatment,while the above situation was effectively improved after fluvastatin intervention.The changes of distribution and expression of TRPC6 were related to podocyte injury induced by PAN.Fluvastatin could exert its protective effects on podocytes by down-regulating TRPC6. 展开更多
关键词 TRPC6 PODOCYTE Puromycin aminonucleoside fluvastatin CALCIUM
原文传递
Silencing of Bcl-2 gene expression by siRNA transfection in- hibits the protective effect of fluvastatin against cell apoptosis in human aortic endothelial cells
7
作者 Wenwen Zhong Yang Liu Jian Li Hui Tian 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2008年第1期33-38,共6页
Objective To study the protective effect of fluvastatin,one of the HMG-CoA reductase inhibitors (statins),against oxygen radical-induced oxidative damages in human aortic endothelial cell,and the role of Bcl-2 in this... Objective To study the protective effect of fluvastatin,one of the HMG-CoA reductase inhibitors (statins),against oxygen radical-induced oxidative damages in human aortic endothelial cell,and the role of Bcl-2 in this protection.Methods Human aortic endothelial cells with or without Bcl-2 siRNA transfection were subjected to 1-100 nM of fluvastatin and 100 la hydrogen peroxide for 24 hours.Bcl-2 mRNA and protein expression were measured by Taqman quantitative PCR and Western blotting.Cell apoptosis was measured by normal and fluorescent microscopy and Cell Death Detection ELISA.Results In the Bcl-2-expressed cells,fluvastatin significantly reversed hydrogen peroxide-induced microscopic apoptosis and apoptotic DNA fragmentation,which were accompanied by a markedly upregulation of Bcl-2 expression by fluvastatin.However,the endothelial protection by fluvastatin was completely lost in Bcl-2 siRNA transfected cells.Conclusion Fluvastatin protects human endothelial cells against oxygen radical-induced cell apoptosis in vitro,and this protection seemed to be mediated in a Bcl-2 dependent pathway.(J Geriatr Cardil 12008;5:33-38) 展开更多
关键词 fluvastatin Bcl-2 gene silencing apoptosis
暂未订购
联用Fluvastatin和环孢菌素的研究
8
《德国临床用药》 2001年第1期30-30,共1页
关键词 肾移植 联合药物治疗 fluvastatin 环孢菌素
暂未订购
Effect of fluvastatin combined with β-receptor-blockers on cardiac function and peripheral blood NF-κB and sST2 in patients with coronary heart disease complicated with heart failure
9
作者 Ai-Min Lu Rong Chen Bao-Bao Liu 《Journal of Hainan Medical University》 2018年第19期14-18,共5页
Objective: To investigate the effects of fluvastatin combined with β-receptor-blockers on cardiac function and peripheral blood NF-κB and sST2 in patients with coronary heart disease (CHD) complicated with heart fai... Objective: To investigate the effects of fluvastatin combined with β-receptor-blockers on cardiac function and peripheral blood NF-κB and sST2 in patients with coronary heart disease (CHD) complicated with heart failure. Methods: A total of 90 CHD patients complicated with heart failure from September 2016 to September 2017 were selected and randomly divided into the control group and the observation group, with 45 cases in each group. The control group was treated with arotinolol and the observation group was treated with arotinolol combined with fluvastatin. The clinical efficacy of the two groups after treatment was compared. The cardiac function index, blood lipid index, inflammatory factor and serum NF-κB and sST2 levels were detected and compared between the two groups. Results: The effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the cardiac function indexes of the two groups were significantly improved (P<0.05). The LVEF and LVFS of the observation group were significantly higher than those of the control group, and LVEDD and LVESD of the observation group were significantly lower those of the control group (P<0.05). The serum lipid index and inflammatory factors of the two groups were significantly decreased after treatment. The hs-CRP, TNF-α, TC and LDL-C of the observation group were significantly lower than those of the control group after treatment (P<0.05). After treatment, the serum NF-κB and sST2 were significantly decreased in both groups, and the serum NF-κB and sST2 in the observation group were significantly lower than those in the control group. There was no significant difference in the incidence of adverse reactions between the two groups (P<0.05). Conclusions: Fluvastatin combined with β-receptor-blockers can reduce the level of blood lipid and inflammatory factors more effectively and improve the clinical efficacy of the CHD patients complicated with heart failure. It can effectively reduce serum NF-κB and sST2 more effectively and improve prognosis. 展开更多
关键词 Coronary HEART disease HEART failure fluvastatin Nuclear factor ΚB Serum soluble matrix LYSIN 2
暂未订购
降血脂药—Fluvastatin(氟圭司汀)
10
作者 朱晓红 《国外新药介绍》 2001年第1期1-4,共4页
关键词 降血脂药 fluvastatin 氟圭司汀 药理学 耐受性
暂未订购
INHIBITORY EFFECT OF FLUVASTATIN ON AORTIC INTIMAL THICKENING IN NORMOCHOLESTEROLEMIC RABBITS 被引量:1
11
作者 叶平 于岱承 +2 位作者 宋立功 邓新心 赵亚力 《Chinese Medical Sciences Journal》 CAS CSCD 2000年第3期140-144,共5页
The anti atherosclerotic effect of fluvastatin at doses insufficient to lower serum cholesterol on the catheter induced intimal thickening and possible mechanism were investigated in abdominal aorta of rabbits. Method... The anti atherosclerotic effect of fluvastatin at doses insufficient to lower serum cholesterol on the catheter induced intimal thickening and possible mechanism were investigated in abdominal aorta of rabbits. Methods.Fifty six rabbits were randomly divided into eight groups(n=7,each).Fluvastatin was given mixed with food at daily dose of8mg/kg starting 5 days before catheterization.Light microscope,immunohistochemistry,transmission electron microscope and RT PCR assay were applied to assess vascular smooth muscle cell (VSMC)proliferation and apoptosis, as well as oncogene expression in vascular wall. Results.At day 10 and day 15 after catheter induced denudation intima/media(I/M)thickness ratio was obviously higher, and also the percentage of PCNA positive cells and TUNEL positive cells in media was significantly higher compared with controls.The intimal hyperplasia was mostly composed of α SM actin positive cells.In rabbits given fluvastatin I/M ratio and the percentage of these positive cells significantly decreased compared with those without fluvastatin.The overexpression of proto oncogene H ras mRNA and decreased expression of anti oncogene p53 mRNA were found after vascular injury,whereas fluvastatin significantly reduced H ras mRNA and increased p53 mRNA expression. Conclusion.Proliferation of VSMC in the media and the migration to the intima can be inhibited,and apoptosis of VSMC be induced by short term use of fluvastatin after balloon catheter denudation,independent of serum lipid change.The underlying mechanism is presumably associated with the influence of fluvastatin on oncogene expression in the injured vascular wall. 展开更多
关键词 HMG CoA reductase inhibitor smooth muscle cells apoptosis
暂未订购
Influence of genetic polymorphisms in drug metabolism enzymes and transporters on pharmacokinetics of different fluvastatin formulations
12
作者 Qian XIANG Jun-yu XU +6 位作者 Ling-yue MA Nan ZHAO Xiao-dan ZHANG Qiu-fen XIE Zhuo ZHANG Xia ZHAO Yi-min CUI 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2018年第4期317-317,共1页
OBJECTIVE The purpose of the present study was to investigate the impact of fluvas.tatin formulation on the pharmacokinetics-genetic polymorphis relationship.METHODS We compared the difference between the pharmacokine... OBJECTIVE The purpose of the present study was to investigate the impact of fluvas.tatin formulation on the pharmacokinetics-genetic polymorphis relationship.METHODS We compared the difference between the pharmacokinetics of fluvastatin as an extended-release(ER) 80 mg tablet and an immediate-release(IR) 40 mg capsule in terms of drug metabolism enzyme and transporter ge.netic polymorphisms.In this open-label,randomized,two-period,two-treatment,crossover study,ef.fects of BCRP,SLCO1B1,MDR1,CYP2C9,and CYP3A5 polymorphisms on the pharmacokinetics of fluvastatin were analyzed in 24 healthy individuals.Each treatment duration was 7 days with a washout period of 7 days between the crossover.Serum concentration of fluvastatin was evaluated using highperformance liquid chromatography-tandem mass spectrometry.RESULTS The SLCO1 B1 T521 C genotype had no statistically significant effect on IR 40 mg capsule of fluvastatinafter single or repeated doses.However,for the ER 80 mg tablet,the SLCO1 B1 T521 C genotype correlated with the AUC_(0-24) of repeat doses(P=0.01).The CYP2C9*3 genotype correlated with the AUC_(0-24) after the first dose IR40 mg capsule(P<0.05);however,the difference between CYP2C9*1/*1 and CYP2 C9*1/*3 was not statistically significant after repeated doses.CONCLUSION The effect of SLCO1B1T521C on fluvas.tatin exposure was observed and was more profound in ER and repeated dose administration than in IR and single dose administration.We recommend that formulation should be incorporated into future pharmacogenomics studies and clinical implication guidelines. 展开更多
关键词 氟伐他汀制剂 药物动力学 遗传学 临床分析
暂未订购
Effects of Fluvastatin on Characteristics of Stellate Ganglion Neurons in a Rabbit Model of Myocardial Ischemia 被引量:4
13
作者 Li-Jun Cheng Guang-Ping Li +2 位作者 Jian Li Yan Chen Xing-Hua Wang 《Chinese Medical Journal》 SCIE CAS CSCD 2016年第5期549-556,共8页
Background:Stellate ganglion(SG)plays an important role in cardiovascular diseases.The electrical activity of SG neurons is involved in the regulation of the autonomic nervous system.The aim of this research was to ev... Background:Stellate ganglion(SG)plays an important role in cardiovascular diseases.The electrical activity of SG neurons is involved in the regulation of the autonomic nervous system.The aim of this research was to evaluate the effects offluvastatin on the electrophysiological characteristics of SG neurons in a rabbit model of myocardial ischemia(MI).Methods:The MI model was induced by abdominal subcutaneous injections of isoproterenol in rabbits.Using whole-cell patch clamp technique,we studied the characteristic changes of ion channels and action potentials(APs)in isolated SG neurons in control group(n=20),MI group(n=20)and fluvastatin pretreated group(fluvastatin group,n=20),respectively.The protein expression of sodium channel in SG was determined by immunohistochemical analysis.Results:MI and the intervention of fluvastatin did not have significantly influence on the characteristics of delayed rectifier potassium channel currents.The maximal peak current density of sodium channel currents in SG neurons along with the characteristics of activation curves,inactivation curves,and recovery curves after inactivation were changed in the MI group.The peak current densities of control group,MI group,and fluvastatin group(n=10 in each group)were-71.77±23.22 pA/pF,-126.75±18.90 pA/pF,and-86.42±28.30 pA/pF,respectively(F=4.862,P=0.008).Fluvastatin can decrease the current amplitude which has been increased by MI.Moreover,fluvastatin induced the inactivation curves and post-inactive recovery curves moving to the position of the control group.But the expression of sodium channel-associated protein(Nav 1.7)had no significantly statistical difference among the three groups.The percentages of Nav 1.7 protein in control group,MI group,and fluvastatin group(n=5 in each group)were 21.49±7.33%,28.53±8.26%,and 21.64±2.78%,respectively(F=1.495,P=0.275).Moreover,MI reduced the electrical activity of AP and increased amplitude of AP,fluvastatin pretreatment could recover amplitude and electrical activity of AP.The probability of neurons induced continuous APs were 44.44%,14.29%,and 28.57%in control group,MI group,and fluvastatin group,respectively.Conclusions:Fluvastatin pretreatment can recover electrophysiology characteristics of ion channel and AP in SG neurons in a rabbit model of MI.It could be considered as potential method for treating coronary heart diseases. 展开更多
关键词 Action Potential Delayed Rectifier Potassium Channel fluvastatin Myocardial Ischemia Sodium Channel Stellate Ganglion
原文传递
Fluvastatin and the Breast Cancer Risk:A Meta-analysis of Observational Studies
14
作者 Dong-Mei Liu Jian Zhang +4 位作者 Wei Zhang James Lu Jian-Lun Han Guang-Jun Hao Sheng-Ming Ye 《World Journal of Traditional Chinese Medicine》 2016年第3期43-47,共5页
Multiple studies have investigated the associations between fluvatatin and the risk of breast cancer(BC),but their results were conflicting.A meta-analysis of observational studies published regarding this subject was... Multiple studies have investigated the associations between fluvatatin and the risk of breast cancer(BC),but their results were conflicting.A meta-analysis of observational studies published regarding this subject was conducted in the present study.It aims to estimate the associations between fluvastatin use and the risk of BC.Pubmed and chinese national knowledge infrastructure(CNKI) database was searched up to January,2015 to identify eligible observational studies,and the Newcastle-Ottawa Scale(NOS) was used to assess quality of the studies.Pooled relative risk(RR) estimates and 95% confidence intervals(CIs) were calculated(fixed effect model:Mantel-Haenszel).Heterogeneities were evaluated before the calculation.A sensitivity analysis was also conducted.In total,four studies contributed to the analysis.Overall,fluvastatin use negatively correlated with BC risk(RR = 0.74,95 % CI = 0.58,0.95).In conclusion,fluvastatin use may reduce the risk of BC,but more research is needed to confirm this finding. 展开更多
关键词 fluvastatin Breast cancer META-ANALYSIS
原文传递
水热反应条件对钨酸铋结构及光催化性能影响 被引量:1
15
作者 刘婷婷 闫梦鸽 +1 位作者 曹利兵 杨帆宇 《功能材料》 北大核心 2025年第2期2143-2150,共8页
通过改变水热反应条件调控钨酸铋(Bi_(2)WO_(6))的形貌结构、晶相结构、比表面积及孔径分布和光电性能,探究水热反应过程对Bi_(2)WO_(6)结构和性能调控机理。结果表明,水热反应温度升高加速前驱液中离子扩散速率和Bi_(2)WO_(6)晶体生长... 通过改变水热反应条件调控钨酸铋(Bi_(2)WO_(6))的形貌结构、晶相结构、比表面积及孔径分布和光电性能,探究水热反应过程对Bi_(2)WO_(6)结构和性能调控机理。结果表明,水热反应温度升高加速前驱液中离子扩散速率和Bi_(2)WO_(6)晶体生长速度,有利于Bi_(2)WO_(6)纳米片自组装和晶体发育,但水热反应温度过高将导致自组装和奥斯特熟化过程过快从而破坏Bi_(2)WO_(6)三维纳米结构,进而导致比表面积和光电性能下降。水热反应时间主要影响Bi_(2)WO_(6)结晶过程,过长的水热反应时间会导致晶体重结晶和团聚,造成光电性能下降。Bi_(2)WO_(6)的优化制备条件为水热反应温度160℃、水热反应时间6 h,该条件下制备的Bi_(2)WO_(6)是正交相的三维纳米花球,具有介孔结构,比表面积达56.95 m^(2)/g,带隙能为2.77 eV,光电性能最佳,对氟伐他汀去除率达69.84%。 展开更多
关键词 钨酸铋 优化制备 水热法 光催化 氟伐他汀
在线阅读 下载PDF
水热反应时间对ZnIn_(2)S_(4)/Bi_(2)WO_(6)复合催化剂结构与性能调控
16
作者 徐战战 刘婷婷 +1 位作者 张强 王磊 《环境科学学报》 北大核心 2025年第5期175-184,共10页
研究了不同水热反应时间对ZnIn_(2)S_(4)/Bi_(2)WO_(6)(ZlS@BW)复合催化剂结构与性能的调控机理.结果表明,随着水热反应时间增加,Bi2WO6由游离颗粒转变为纳米花瓣状并紧密附着在ZnIn2S4表面形成具有核壳结构的ZlS@BW复合催化剂.水热反... 研究了不同水热反应时间对ZnIn_(2)S_(4)/Bi_(2)WO_(6)(ZlS@BW)复合催化剂结构与性能的调控机理.结果表明,随着水热反应时间增加,Bi2WO6由游离颗粒转变为纳米花瓣状并紧密附着在ZnIn2S4表面形成具有核壳结构的ZlS@BW复合催化剂.水热反应时间较短时,ZlS@BW复合催化剂结晶程度较低,水热反应时间过长时重结晶导致晶体结构被破坏.当反应时间增加,形貌结构变化导致ZlS@BW复合催化剂比表面积先增大后减小,同时光生电子-空穴传输通道发生变化改善了光生电子-空穴对的分离性能,使得光催化性能显著提升.水热时间为720 min时制备的ZlS@BW复合催化剂结晶程度较高且形貌致密,具有最大的比表面积和瞬态光电流,阻抗半径最小,光生电子空穴分离性能最佳,有利于光催化反应过程中更多的光生电子和空穴迁移到催化剂表面进行光催化反应,光催化降解氟伐他汀效率可达到75.47%. 展开更多
关键词 水热法 反应时间 ZnIn_(2)S_(4)/Bi_(2)WO_(6)复合催化剂 光催化 氟伐他汀
原文传递
基于美国FAERS/加拿大CVARD数据库的他汀类药物与甲状腺不良事件的药物警戒研究
17
作者 曹玉合 肖亚平 +3 位作者 徐寅鹏 王云龙 黄鹂 徐才兵 《药物评价研究》 北大核心 2025年第8期2253-2262,共10页
目的 借助加拿大药物警戒不良事件在线数据库(CVARD)和美国食品药品监督管理局不良事件报告系统(FAERS)挖掘和分析他汀类药物与甲状腺不良事件的关联性,为临床安全用药提供参考。方法 收集CVARD数据库1991年1月—2024年6月,FAERS数据库2... 目的 借助加拿大药物警戒不良事件在线数据库(CVARD)和美国食品药品监督管理局不良事件报告系统(FAERS)挖掘和分析他汀类药物与甲状腺不良事件的关联性,为临床安全用药提供参考。方法 收集CVARD数据库1991年1月—2024年6月,FAERS数据库2004年第一季度—2024年第二季度期间接收到的他汀类药物相关的甲状腺不良事件的报告。采用报告比值比法(ROR)、比例报告比值比法(PRR)和贝叶斯置信区间传播神经网络法(BCPNN)检测他汀类药物的风险信号。结果 共检索到他汀类药物相关的甲状腺不良事件253例,其中阿托伐他汀、瑞舒伐他汀、普伐他汀、氟伐他汀的报告数分别为129、111、10、3例;检测发现了阿托伐他汀相关的甲状腺癌、甲状腺肿和甲状腺疾病3个不良事件风险信号,瑞舒伐他汀相关的甲状腺肿、甲状腺疾病和促甲状腺激素升高3个风险信号,普伐他汀相关的甲状腺功能减退不良事件风险信号,氟伐他汀相关的自身免疫性甲状腺炎不良事件风险信号。在FAERS数据库中,氟伐他汀相关的自身免疫性甲状腺炎风险信号最高(ROR=23.074);在CVARD数据库中,普伐他汀相关的甲状腺功能减退风险信号最高(ROR=13.66)。检索发现甲状腺不良事件在用药后31~90 d内诱发的病例占比最大(65.4%),使用阿托伐他汀的女性患者表现出更高的甲状腺疾病、甲状腺肿和甲状腺癌风险信号,而使用瑞舒伐他汀的男性患者则更易出现甲状腺疾病、甲状腺肿和促甲状腺激素升高的风险信号。诱发甲状腺不良事件的阿托伐他汀和氟伐他汀的累积日剂量平均数和最大剂量均在我国药品说明书正常范围内,但是瑞舒伐他汀和普伐他汀相关累积日剂量均超过我国药品说明书最大剂量范围。结论 对FAERS/CVARD数据库的药物警戒分析显示,阿托伐他汀、瑞舒伐他汀和氟伐他汀与甲状腺不良事件的风险存在一定关联。 展开更多
关键词 他汀类药物 甲状腺不良事件 CVARD数据库 FAERS数据库 阿托伐他汀 瑞舒伐他汀 普伐他汀 氟伐他汀
原文传递
氟伐他汀联合达格列净治疗2型糖尿病伴轻度肥胖患者的临床分析 被引量:1
18
作者 裴晓庆 《四川生理科学杂志》 2025年第7期1575-1577,1587,共4页
目的:探讨氟伐他汀联合达格列净治疗对2型糖尿病(Type 2 diabetes mellitus,T2DM)伴轻度肥胖患者血糖、血脂、体脂的影响。方法:选取2022年6月~2024年3月期间本院接收的144例T2DM伴轻度肥胖患者为研究对象。采用随机数字表法将144例T2D... 目的:探讨氟伐他汀联合达格列净治疗对2型糖尿病(Type 2 diabetes mellitus,T2DM)伴轻度肥胖患者血糖、血脂、体脂的影响。方法:选取2022年6月~2024年3月期间本院接收的144例T2DM伴轻度肥胖患者为研究对象。采用随机数字表法将144例T2DM伴轻度肥胖患者分为对照组和观察组,每组各57例。对照组给予达格列净治疗,10 mg·次^(-1),1次·d^(-1);观察组在对照组基础上联合氟伐他汀治疗,40 mg·次^(-1),1次·d^(-1),两组连续治疗3 m。分析比较两组血糖[空腹血糖(Fasting blood glucose,FBG)、餐后2 h血糖(2 hours postprandial blood glucose,2 hPG)、糖化血红蛋白(HemoglobinA1c,HbA1c)、空腹胰岛素(Fasting insulin,FINS)、胰岛β细胞功能指数(Homeostasis model assessment-β,HOMA-β)、胰岛素抵抗指数(Homeostasis model assessment for insulin resistance,HOMA-IR)]、血脂[甘油三酯(Triglyceride,TG)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)水平、总胆固醇(Total cholesterol,TC)、高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)、脂联素]、体脂[腰围、体脂率、体质量指数(Body Mass Index,BMI)]及不良反应。结果:治疗后两组2hPG、FINS、HbA1c、FBG、HOMA-IR降低,HOMA-β水平升高,且观察组改善幅度大于对照组(P<0.05)。治疗后观察脂联素、HDL-C水平高于对照组,TC、LDL-C、TG水平低于对照组(P<0.05)。治疗后观察组腰围、体脂率及BMI水平低于对照组(P<0.05)。两组的不良反应发生率无显著差异(P>0.05)。结论:氟伐他汀联合达格列净治疗能改善T2DM伴轻度肥胖患者血糖、血脂水平,降低体脂,且安全性良好。 展开更多
关键词 氟伐他汀 达格列净 2型糖尿病 肥胖 血脂
暂未订购
水热反应前驱液pH对钨酸铋形貌结构及光催化性能调控
19
作者 刘婷婷 曹利兵 +3 位作者 吴颜 闫梦鸽 杨帆宇 武峥 《工程科学学报》 北大核心 2025年第4期958-969,共12页
氟伐他汀作为常用的降血脂药物,常随人体排泄物排入水体.环境水体中的氟伐他汀很难被自然光所降解,长期累积会对环境构成一定的威胁.本研究采用钨酸铋(Bi_(2)WO_(6))可见光催化降解氟伐他汀,研究不同水热反应前驱液pH制备Bi_(2)WO_(6)... 氟伐他汀作为常用的降血脂药物,常随人体排泄物排入水体.环境水体中的氟伐他汀很难被自然光所降解,长期累积会对环境构成一定的威胁.本研究采用钨酸铋(Bi_(2)WO_(6))可见光催化降解氟伐他汀,研究不同水热反应前驱液pH制备Bi_(2)WO_(6)的形貌结构及光电性能变化规律,结合活性自由基及中间产物解析揭示氟伐他汀降解机理.结果表明,前驱液pH由酸性转向中性时Bi_(2)WO_(6)晶体发育过程被破坏引起纳米片堆叠,前驱液pH为碱性时形成无序的八面体物相高聚体.随着pH升高,Bi_(2)WO_(6)的比表面积和孔径逐渐减小.当pH值为0.5时,Bi_(2)WO_(6)呈现有序的三维纳米花球结构,具有最佳光催化性能,光照120 min后氟伐他汀降解率达69.84%.经过四轮循环实验后,催化剂性能仍较为稳定.电化学实验结果表明,当前驱液pH值为0.5时,Bi_(2)WO_(6)具有最佳的光生电子-空穴(e^(-)-h^(+))分离性能,进而促进活性自由基高效产生.自由基实验结果表明,在降解过程中h^(+)发挥主要的氧化作用,·OH和·O_(2)^(-)起辅助作用.Bi_(2)WO_(6)降解氟伐他汀的机理是以h^(+)为主,·OH和·O_(2)^(-)为辅,联合攻击氟伐他汀分子的C-C键,形成小分子环状有机物、直链有机物和羟基化衍生物,进而将其矿化为CO_(2)和H_(2)O. 展开更多
关键词 钨酸铋 氟伐他汀 水热反应 前驱液pH 光催化性能
在线阅读 下载PDF
他汀类药物抗肿瘤作用机制的新进展
20
作者 章天成 《中国卫生标准管理》 2025年第16期190-194,共5页
他汀类药物是临床常用的调脂药物,其作用机制是通过对羟基甲基戊二酸酰辅酶A(hydroxylmethylglutaryl coenzyme A;HMG-CoA)还原酶进行抑制,以此达到降脂的目的。近年来,他汀类药物的抗肿瘤作用逐步被发现。药物通过阻断甲羟戊酸代谢,降... 他汀类药物是临床常用的调脂药物,其作用机制是通过对羟基甲基戊二酸酰辅酶A(hydroxylmethylglutaryl coenzyme A;HMG-CoA)还原酶进行抑制,以此达到降脂的目的。近年来,他汀类药物的抗肿瘤作用逐步被发现。药物通过阻断甲羟戊酸代谢,降低类异戊二醛的合成,阻止小G蛋白发生异戊二烯基化,影响肿瘤细胞增殖、迁移和侵袭等相关信号传导。文章从他汀类药物及肿瘤相关概述出发,从而明确药物抑制肿瘤细胞增殖、促进细胞凋亡、抑制肿瘤侵袭转移、抗肿瘤血管新生和抗肿瘤免疫等作用,阐述不同药物的分子机理及作用机制,旨在为他汀类药物应用于肿瘤防治奠定理论基础。 展开更多
关键词 他汀类药物 抗肿瘤 作用机制 氟伐他汀 普伐他汀 研究进展
暂未订购
上一页 1 2 35 下一页 到第
使用帮助 返回顶部